Understanding how PIM2 helps multiple myeloma cells survive
Official title: Novel pro-survival mechanisms of PIM2 in multiple myeloma
Funded at Indiana University Indianapolis · NIH-11056768 · Data updated 2026-11-12
This study is looking at a protein called PIM2 that might help multiple myeloma cells survive treatment, and by understanding how it works, researchers hope to find new ways to make treatments more effective for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | April 15, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $571,063 |
| NIH project number | 5R01CA272852-03 |
| Project ID | NIH-11056768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancers or those who do not have multiple myeloma may not benefit from this research.
What this research studies
This research investigates the role of PIM2, a protein that may help multiple myeloma cells resist treatment. By examining how PIM2 is regulated and its effects on cancer cell survival, the study aims to identify new therapeutic targets that could improve treatment outcomes. The researchers will use advanced techniques to analyze the expression and activity of PIM2 in multiple myeloma cells, particularly focusing on a novel inhibitor that selectively targets PIM2. This approach could lead to more effective treatments for patients with this challenging cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve survival rates and treatment responses for patients with multiple myeloma.
How similar studies have gone: Previous research has shown promise in targeting PIM kinases for cancer treatment, suggesting that this approach could be a meaningful advancement in the field.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Lee, Kelvin P. — Indiana University Indianapolis
- Study coordinator: Lee, Kelvin P.
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.